Inozyme Pharma (NASDAQ:INZY) Given New $30.00 Price Target at Piper Sandler

Inozyme Pharma (NASDAQ:INZY - Get Free Report) had its target price reduced by research analysts at Piper Sandler from $43.00 to $30.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an "overweight" rating on the stock.

Several other research analysts have also issued reports on INZY. Wedbush reiterated an "outperform" rating and issued a $12.00 price target on shares of Inozyme Pharma in a research note on Friday. Raymond James assumed coverage on shares of Inozyme Pharma in a research note on Thursday, December 12th. They issued an "outperform" rating and a $26.00 price objective on the stock. HC Wainwright upped their price target on Inozyme Pharma from $14.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Needham & Company LLC restated a "buy" rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $18.33.

Inozyme Pharma Stock Performance

NASDAQ:INZY traded down $0.28 during trading on Monday, reaching $1.72. The company's stock had a trading volume of 1,516,904 shares, compared to its average volume of 918,272. The firm has a market cap of $110.49 million, a price-to-earnings ratio of -1.10 and a beta of 1.35. The firm has a 50 day moving average of $2.96 and a 200-day moving average of $4.36. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. Inozyme Pharma has a 12 month low of $1.61 and a 12 month high of $7.80.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05. Research analysts expect that Inozyme Pharma will post -1.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of INZY. JPMorgan Chase & Co. lifted its holdings in shares of Inozyme Pharma by 31.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company's stock worth $151,000 after buying an additional 6,851 shares during the period. Virtu Financial LLC bought a new stake in shares of Inozyme Pharma in the third quarter valued at about $64,000. Barclays PLC lifted its stake in Inozyme Pharma by 261.4% in the third quarter. Barclays PLC now owns 76,730 shares of the company's stock worth $401,000 after acquiring an additional 55,497 shares during the period. Geode Capital Management LLC grew its holdings in Inozyme Pharma by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company's stock worth $6,126,000 after acquiring an additional 19,499 shares in the last quarter. Finally, Jane Street Group LLC increased its position in Inozyme Pharma by 7.5% during the 3rd quarter. Jane Street Group LLC now owns 49,460 shares of the company's stock valued at $259,000 after purchasing an additional 3,443 shares during the period. Institutional investors own 88.30% of the company's stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.